(Q42966589)

11 November 2017

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury (English)

1 reference

11 November 2017

Jonathan B Singer

1

1 reference

11 November 2017

Steve Lewitzky

2

1 reference

11 November 2017

Elisabeth Leroy

3

1 reference

11 November 2017

Fan Yang

4

1 reference

11 November 2017

Xiaojun Zhao

5

1 reference

11 November 2017

Lloyd Klickstein

6

1 reference

11 November 2017

Timothy M Wright

7

1 reference

11 November 2017

Joanne Meyer

8

1 reference

11 November 2017

Charles A Paulding

9

1 reference

11 November 2017

language of work or name

English

0 references

publication date

18 July 2010

1 reference

11 November 2017

1 reference

11 November 2017

42

1 reference

11 November 2017

711-714

1 reference

11 November 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/ng.632

11 November 2017

0 references

cites work

Lumiracoxib in the management of osteoarthritis and acute pain

1 reference

Drug hepatotoxicity from a regulatory perspective

21 January 2018

1 reference

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

Drug-related hepatotoxicity

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

21 January 2018

1 reference

Idiosyncratic drug reactions: current understanding

21 January 2018

1 reference

Pharmacological interaction of drugs with immune receptors: the p-i concept.

21 January 2018

1 reference

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

HLA association of amoxicillin-clavulanate--induced hepatitis

21 January 2018

1 reference

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

PLINK: a tool set for whole-genome association and population-based linkage analyses

21 January 2018

1 reference

Hy's law: predicting serious hepatotoxicity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20639878

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20639878

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NG.632

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference